Morgan Stanley Initiates Coverage on Pharmasset (VRUS)
More News related to VRUS
- Pharmasset Reports Fiscal Year End 2009 Financial Results
- Pharmasset (VRUS) Reports Inline Q4 Loss of $0.53
- Pharmasset (VRUS) and Roche Announce Continuing Enrollment for Cohort 2 Phase 2b
- Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
- Unusual 11 Mid-Day Movers 11/18: ABK, LZB, NLST, LDK Higher; ONCY, NANO, EXEL, VRUS Lower
More News related to New Coverage
- Pritchard Capital Initiates Coverage on Construction Services Stocks
- Sidoti & Co Initiates Coverage on Scholastic (SCHL) with a Buy
- Raymond James Initiates Coverage on Movie Production, Theater Stocks
- C. K. Cooper & Company Initiates Coverage on Atwood Oceanics (ATW) with a Buy
- Macquarie Initiates Coverage on Comverge (COMV) with an Outperform
Morgan Stanley initiates coverage on Pharmasset (Nasdaq: VRUS) with an Equalweight.
Pharmasset, Inc. (Pharmasset) is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections.
Related Categories
New CoverageStocks Mentioned
+0.21Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
